163 related articles for article (PubMed ID: 28484014)
1. Selective targeting of point-mutated KRAS through artificial microRNAs.
Acunzo M; Romano G; Nigita G; Veneziano D; Fattore L; Laganà A; Zanesi N; Fadda P; Fassan M; Rizzotto L; Kladney R; Coppola V; Croce CM
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4203-E4212. PubMed ID: 28484014
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
Zarredar H; Pashapour S; Ansarin K; Khalili M; Baghban R; Farajnia S
J Cell Physiol; 2019 Feb; 234(2):1560-1566. PubMed ID: 30132854
[TBL] [Abstract][Full Text] [Related]
3. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer.
Sun CC; Li SJ; Zhang F; Pan JY; Wang L; Yang CL; Xi YY; Li de J
Oncotarget; 2016 Apr; 7(16):21510-26. PubMed ID: 26909600
[TBL] [Abstract][Full Text] [Related]
4. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
5. Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade.
Umelo IA; De Wever O; Kronenberger P; Van Deun J; Noor A; Singh K; Teugels E; Chen G; Bracke M; De Grève J
Oncotarget; 2015 Aug; 6(24):20132-44. PubMed ID: 25992771
[TBL] [Abstract][Full Text] [Related]
6. MiR-181a-5p inhibits cell proliferation and migration by targeting Kras in non-small cell lung cancer A549 cells.
Ma Z; Qiu X; Wang D; Li Y; Zhang B; Yuan T; Wei J; Zhao B; Zhao X; Lou J; Jin Y; Jin Y
Acta Biochim Biophys Sin (Shanghai); 2015 Aug; 47(8):630-8. PubMed ID: 26124189
[TBL] [Abstract][Full Text] [Related]
7. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
8. Combined Delivery of Let-7b MicroRNA and Paclitaxel via Biodegradable Nanoassemblies for the Treatment of KRAS Mutant Cancer.
Dai X; Fan W; Wang Y; Huang L; Jiang Y; Shi L; Mckinley D; Tan W; Tan C
Mol Pharm; 2016 Feb; 13(2):520-33. PubMed ID: 26636714
[TBL] [Abstract][Full Text] [Related]
9. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
10. A KRAS-responsive long non-coding RNA controls microRNA processing.
Shi L; Magee P; Fassan M; Sahoo S; Leong HS; Lee D; Sellers R; Brullé-Soumaré L; Cairo S; Monteverde T; Volinia S; Smith DD; Di Leva G; Galuppini F; Paliouras AR; Zeng K; O'Keefe R; Garofalo M
Nat Commun; 2021 Apr; 12(1):2038. PubMed ID: 33795683
[TBL] [Abstract][Full Text] [Related]
11. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
[TBL] [Abstract][Full Text] [Related]
12. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14).
Wang R; Wang ZX; Yang JS; Pan X; De W; Chen LB
Oncogene; 2011 Jun; 30(23):2644-58. PubMed ID: 21358675
[TBL] [Abstract][Full Text] [Related]
14. miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway.
Yu SH; Zhang CL; Dong FS; Zhang YM
J Cell Biochem; 2015 Feb; 116(2):268-76. PubMed ID: 25187230
[TBL] [Abstract][Full Text] [Related]
15. The candidate oncogene (MCRS1) promotes the growth of human lung cancer cells via the miR-155-Rb1 pathway.
Liu M; Zhou K; Huang Y; Cao Y
J Exp Clin Cancer Res; 2015 Oct; 34():121. PubMed ID: 26467212
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
Srikar R; Suresh D; Zambre A; Taylor K; Chapman S; Leevy M; Upendran A; Kannan R
Sci Rep; 2016 Aug; 6():30245. PubMed ID: 27530552
[TBL] [Abstract][Full Text] [Related]
17. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
18. RNAi-mediated A disintegrin and metalloproteinase 9 gene silencing inhibits the tumor growth of non-small lung cancer in vitro and in vivo.
Chang L; Gong F; Cui Y
Mol Med Rep; 2015 Jul; 12(1):1197-204. PubMed ID: 25778452
[TBL] [Abstract][Full Text] [Related]
19. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS.
Fu X; Cui Y; Yang S; Xu Y; Zhang Z
Tumour Biol; 2016 May; 37(5):6477-83. PubMed ID: 26631045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
